Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 5 January 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Compa

Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

AUSTRALIA AND SAN FRANCISCO, USA - 5 January 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or

"the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,

today announced that David Stamler, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking

place January 10-13, 2022.

presentation will be accessible on the Alterity website under News on Monday, January 10, 2022 at 7:00 a.m. ET.

Alterity Therapeutics Limited

Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative

diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad

drug discovery platform generating patentable chemical compunds to intercede in disease processes. The Company is based in Melbourne,

Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

& Additional information

announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section

21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as

"expects," "intends," "hopes," "anticipates," "believes," "could," "may,"

"evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying

factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in

the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on

Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development

program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program,

including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties,

including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing,

regulatory approval, production and marketing of the Company's drug components, including, but not limited to, ATH434, uncertainties

relating to the impact of the novel coronavirus (COVID-19) pandemic on the company's business, operations and employees, the ability

of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy

of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent productscomingtomarket, the uncertaintyof

obtaining patent protectionfor the Company's intellectualproperty or trade secrets, the uncertainty of successfully enforcing the Company's

patent rights and the uncertainty of the Company freedom to operate.

forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as

of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral,

that may be made from time to time, whether as a result of new information, future developments or otherwise.